Results 41 to 50 of about 2,672,729 (207)

Recent developments in MOG-IgG associated neurological disorders

Therapeutic Advances in Neurological Disorders, 2020
In the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica ...
Harald Hegen, Markus Reindl
doaj   +1 more source

Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations

, 2017
Jinming Han,1 Meng-ge Yang,1 Jie Zhu,1,2 Tao Jin1 1Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China; 2Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
Jin, T, Zhu, J,, Zhu J, Yang M, Jin T, Han, J, Yang, M-G, Han J   +7 more
core   +1 more source

Research progress of neuroregeneration in neuromyelitis optica spectrum disorders

Chinese Journal of Contemporary Neurology and Neurosurgery, 2022
In the treatment of neurological diseases, neuroregeneration is a contentious and challenging issue. Our understanding of the mechanisms related to neuroregeneration in neuromyelitis optica spectrum disorders (NMOSDs) is currently restricted and there ...
QIU Wei , LUO Wen⁃jing
doaj   +1 more source

Neuromyelitis Optica Spectrum Disorders (NMOSD); Diagnostic criteria (ORP-56) [PDF]

Neurology Letters, 2023
Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune astrocytopathy. The term NMOSD is used as an umbrella term that refers to Aquaporin-4 (IgG) positive NMO and some closely related clinical syndromes without AQP4-IgG. Core clinical features
Maryam Poursadeghfard
doaj  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Neuromyelitis optica spectrum disorder

Brain and nerve = Shinkei kenkyu no shinpo, 2021
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder primarily associated with optic neuritis, myelitis or area postrema syndrome. Several lines of evidence suggest that NMOSD is a humoral immune disease mainly caused by aquaporin-4 antibody and related complement-dependent cytotoxicity against astrocytes.
openaire   +3 more sources

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Neuromyelitis optica spectrum disorder – case report

, 2016
The study presents the case of a 45-year-old woman with a rare case of Devic’s disease (neuromyelitis optica – NMO) admitted to the Department of Rehabilitation in Kielce.
Marta Mierzwa-Molenda, Grażyna Ściegienna-Zdeb   +1 more
core   +1 more source

MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives The study aimed to characterize the clinical features, etiologies, and outcomes of isolated, first‐time pediatric ON in the post‐MOG‐IgG era. Methods This was a single‐center retrospective cohort study at Texas Children's Hospital of patients diagnosed with first‐time ON between 2018–2024, with follow‐up data collected through 2025.
Chaitanya Aduru, Akansha Chandrasekar, Kyla Blasingame, Jonathan Rosen, Jesse M. Levine, Karla Salazar, Madhuri Chilakapati, Rod Foroozan, Victoria Hardwick, Jonathan M. Yarimi, Nikita Shukla, Timothy E. Lotze, Kristen S. Fisher, Alexander J. Sandweiss   +13 more
wiley   +1 more source

Differential diagnosis of neuromyelitis optica spectrum disorders

Therapeutic Advances in Neurological Disorders, 2017
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system (CNS) mostly manifesting as optic neuritis and/or myelitis, which are frequently recurrent/bilateral or longitudinally extensive, respectively.
Sung-Min Kim, Seong-Joon Kim, Haeng Jin Lee, Hiroshi Kuroda, Jacqueline Palace, Kazuo Fujihara   +5 more
doaj   +1 more source